Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France. (CAROLINE)

Ipsen

Status: Withdrawn

Conditions: Renal Cell Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT04609800

A-FR-60000-070

Details and patient eligibility

About

The purpose of the protocol is to assess the Overall Survival (OS) at 1 year in patients after cabozantinib initiation.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female ≥ 18 age at the time of cabozantinib initiation
• Pathologically confirmed diagnosis of Renal Cell Carcinoma (Clear Cell or non-Clear Cell) cancer considered as advanced or metastatic at the time of cabozantinib initiation
• Intention to be treated with cabozantinib tablets according to the current local Summary of Product Characteristics (SmPC) (France)
• Initiating cabozantinib as a second line of treatment (Baseline visit must be performed before cabozantinib first intake)

Exclusion criteria

• He/she is already included in an interventional trial with an investigational product at the same time.